Abstract: 672: SP-101 activity increases in a dose dependent manner to both vector and doxorubicin dose. North American Cystic Fibrosis Conference 2022
Abstract: 621: Administration of SP-101 and doxorubicin results in robust and durable human cystic fibrosis transmembrane conductance regulator minigene transgene expression in the airways of ferrets and corrects human cystic fibrosis airway epithelia in vitro. North American Cystic Fibrosis Conference 2022
<a href="https://spirovant.com/wp-content/uploads/2022/03/NACFC-SP-101_POSTER_Master-9-22-2181-Read-Only-1.pdf">Katherine Excoffon: Delivery of SP-101 restores CFTR function in human CF airway epithelial cultures and drives hCFTRΔR transgene expression in the airways of ferrets. North American Cystic Fibrosis Conference 2021. – Poster</a>
<a href="https://www.mdpi.com/2073-4425/10/3/218"> Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease </a>
<a href="https://pubmed.ncbi.nlm.nih.gov/25763813/">Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers </a>
<a href="https://pubmed.ncbi.nlm.nih.gov/19237554/">Directed evolution of adeno-associated virus to an infectious respiratory virus</a>
<a href="https://pubmed.ncbi.nlm.nih.gov/15564131/">Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway</a>
<a href="https://pubmed.ncbi.nlm.nih.gov/14990705/">Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia</a>